MISSISSAUGA, ON, Feb. 29 /CNW/ - MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company") is pleased to announce that it has entered into an agreement (the "Agreement") with Taddle Creek Capital ("TCC") whereby TCC will provide a variety of advisory services, including services related to capital markets, for a period of two years ending January 31, 2010.
TCC will be paid a monthly retainer of $5,000 and 100,000 options per year over the course of the Agreement.
"We are very pleased to continue our relationship with Taddle Creek Capital," said Gary Van Nest, MedX's Chairman and acting President. "Nelson Smith was instrumental in our success in raising capital and becoming listed on the TSX Venture Exchange, and, particularly in the difficult times in which we currently find our selves, we look forward to his continued guidance and advice as we grow the business."
About Taddle Creek Capital
TCC was founded in 2007 to provide advice to companies seeking to access the Canadian public equities markets for the first time. TCC works closely with its clients every step of the way through the process, from initial meeting to final closing, and then works to help the client meet its capital markets goals in the after-market. TCC was founded by Nelson Smith, a former investment banker with over 20 years of experience in surfacing companies into the Canadian public markets. Nelson has worked with some of Canada's most successful companies in their earliest stages of "being public".
About MedX Health Corp.
MedX is a leading North American developer and manufacturer of phototherapy medical devices, including dental, rehabilitation and wound care products. MedX plans to use the proceeds from its recent public offering to, amongst other things, accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this press release.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
%SEDAR: 00017466E